GlassScriptPhysician profile
Kyle Y Echols
NPI 1427135946
$4,075.78
in general payments reported to CMS, 2019-2025
23 companies · $817 in 2025
The $817 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $409 · 2021: $235 · 2022: $309 · 2023: $716 · 2024: $901 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $508.93 | 2019-2025 | Trintellix |
| Corium, LLC | $471.66 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $301.52 | 2021-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $289.27 | 2019-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $287.49 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $284.22 | 2019-2025 | Spravato |
| Neos Therapeutics, LP | $280.82 | 2019-2024 | Cotempla Xr-Odt |
| Abbvie INC. | $264.40 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $251.07 | 2019-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $242.70 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.41 | 2022-2025 | Caplyta |
| Lundbeck LLC | $165.52 | 2019-2025 | Rexulti |
| Tris Pharma INC | $138.57 | 2019-2025 | Dyanavel Xr |
| Alkermes, INC. | $89.22 | 2022-2024 | Aristada, Lybalvi |
| Almatica Pharma LLC | $73.76 | 2022-2025 | Loreev Xr, Sertraline Hcl |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $54.84 | 2019-2025 | Relexxii |
| Shire North American Group INC | $50.27 | 2019 | |
| Adlon Therapeutics L.P. | $29.96 | 2019-2020 | |
| Noven Therapeutics, LLC | $22.91 | 2024 | Secuado, Xelstrym |
| Teva Pharmaceuticals USA, INC. | $22.20 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.53 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.52 | 2019 | |
| Allergan, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Echols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.